[ad_1]
Refinery29
It is the first retinoid to safely treat acne on your face, chest, shoulders and back
When it comes to acne, the conversation is usually about how to treat it or how it can lead to anxiety, depression, and low self-esteem.1 It’s usually about de-stigmatizing a skin problem so widespread that it affects up to 50 million Americans each year.2 Usually it is facial acne. According to certified dermatologist Dr. Julie Harper, body acne is not as discussed as facial acne – despite being quite common. For Dr. Harper, it affects more than half of her patients with facial acne3. [the medical term for ‘chest, shoulders, and back’] acne can present its own challenges, ”she explains. “There is a difference in the way we treat facial and trunk acne, but the difference in treatment approach has historically not been based on evidence or data. Ultimately, we tend to outsource acne on the trunk. He tends to be out of sight, out of mind. For this reason, Dr Harper says there have been no proven treatments for body acne – so far with Galderma’s AKLIEF® (Trifarotene) Cream, 0.005%, indicated for the treatment of acne that has been shown to be safe for the face, chest, It is an innovative prescription retinoid – the first retinoid molecule to be approved by the FDA in more than 20 years for the treatment of ‘acne.5 The retinoid molecule (active ingredient) is trifarotene, which specifically targets important factors “This selectivity of trifarotene means that the product is potent even at low concentrations,” says Dr Harper, who is also a carrier. -paid speech from Galderma.7 “This low concentration confirms us from a safety point of view to use it. on larger areas, such as the chest and back. 4 Once you have seen a dermatologist and AKLIEF Cream is prescribed, use as your doctor tells you, applying a thin layer (one face pump, two chest, shoulder, and back pumps) and av by protecting the sun by using sunscreen and protective clothing – after that you may find that acne improves as early as two weeks. [your acne] is mild to moderate or severe, or on the face or trunk, it can be treated, ”says Dr. Harper. IMPORTANT SAFETY INFORMATION: Indication: AKLIEF ® (trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older Adverse reactions: The most common adverse reactions ( incidence ≥ 1%) in patients treated with AKLIEF Cream were application site irritation, application site pruritus (itching), and sunburn. Warnings / Precautions: Patients using AKLIEF Cream may experience erythema, scaling, dryness and stinging / burning. Use a moisturizer from the start of treatment and, if necessary, depending on the severity of these side effects, reduce the frequency of application of AKLIEF Cream, suspend or discontinue use. Avoid applying AKLIEF Cream to cuts, abrasions, or eczematous or sunburned skin. The use of “waxing” as a depilatory method should be avoided on skin treated with AKLIEF cream. Minimize exposure to the sun and sunlamps. Use sunscreen and protective clothing on treated areas when exposure cannot be avoided. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. All trademarks are the property of their respective owners. This information does not constitute medical advice. Talk to your doctor about your medical problems. 1 American Academy of Dermatology. Acne can affect more than your skin. https://www.aad.org/public/diseases/acne-and-rosacea/emotional-health-effects-of-acne. Accessed August 23, 2019 2 Chiu A. et al. The response of skin disease to stress. Bitter. Medical Assoc. 2003. 139: 897-900.3 Del Rosso JQ et al. A Closer Look at Truncal Acne Vulgaris: Prevalence, Severity, and Clinical Significance. J Drugs Dermatol. 2007; 6: 597-600.4 Tan J, Thiboutot D, Popp G, Gooderham M, Lynde C, et al. Randomized phase 3 evaluation of trifarotene cream 50 μg / g treatment for moderate facial and trunk acne. J Am Acad Dermatol. 2019. DOI: https://doi.org/10.1016/j.jaad.2019.02.044.5 British Association of Dermatologists. Topical trifarotene: a new retinoid. Br J Dermatol. 2018; 179: 231-232. 6 Fisher GJ et al. J Biol Chem 1994; 269 (32): 20629-35. 7Aubert J, Piwnica D, Bertino B, Blanchet-Réthoré S, Carlavan I, et al. Non-clinical and human pharmacology of the potent and selective topical retinoic acid receptor agonist trifarotene. Br J Dermatol. 2018; 179: 442-456. Like what you see? How about a little more R29 goodness, here?
[ad_2]
Source link